Diabetes and Obesity Drug Boom to Propel Lilly and Novo Nordisk to Pharma Sales Leadership by 2030: Evaluate

on

According to Evaluate’s latest analysis, five obesity and diabetes drugs from Eli Lilly and Novo Nordisk are projected to dominate the top 10 bestselling drugs globally by 2030, signaling a major industry shift away from oncology towards metabolic disease treatments.5

Lilly’s tirzepatide-based products (Mounjaro and Zepbound) and Novo Nordisk’s semaglutide-based medicines (Ozempic, Wegovy, and CagriSema) are expected to collectively garner over $100 billion in annual sales by the end of the decade.5

The Evaluate 2024 world preview report highlights that these metabolic medicines are rapidly overtaking long-reigning oncology drugs in market prominence, reflecting new, more predictable growth realities for pharma.5

The projected boom is fueled by the global surge in obesity and type 2 diabetes rates, along with heightened demand for effective pharmacological interventions.13

Analysts predict the global obesity and weight-loss drug market will approach or exceed $150 billion in value by the early 2030s, underscoring the commercial potential for companies leading this therapeutic area.4

Sources:

1. https://www.grandviewresearch.com/industry-analysis/obesity-treatment-devices-and-therapeutics-market

3. https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs

4. https://www.biospace.com/obesity-market-to-reach-150b-as-demand-grows-supply-stabilizes-reuters

5. https://www.fiercepharma.com/pharma/move-over-oncology-obesity-diabetes-meds-will-take-over-2030s-top-drug-rankings-evaluate